RxDoctor Payments Data

Shelby Adney, NP

Family · Sacramento, CANPI 1316646847

Payments from drug & device makers

$1,395in general payments, 2019–2025

Across 35 payments — averaging $39.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$460
  • Lilly USA, LLC$157
  • GSK$132
  • Cook Medical LLC$126
  • Novo Nordisk$117
  • Tactile Systems Technology Inc$100
  • plus $303 from 7 others

What the payments were for

  • Food & beverage$1,395100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,395 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$25,533
Medicare patients
163
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$52,218
OzempicSemaglutide37$49,083
JardianceEmpagliflozin24$37,437
RybelsusSemaglutide15$32,106
FarxigaDapagliflozin Propanediol18$28,841
TrulicityDulaglutide11$18,331
XareltoRivaroxaban14$12,050
Atorvastatin Calcium163$2,014
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen78$1,494
Albuterol Sulfate HfaAlbuterol Sulfate51$1,440
SynthroidLevothyroxine Sodium19$1,262
Gabapentin68$1,236
Tamsulosin Hcl42$1,107
Losartan Potassium79$1,086
Omeprazole53$1,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$117$81,18952 claims
PfizerEliquis$22$52,21871 claims
AstraZenecaFarxiga$78$28,84118 claims
Lilly USA, LLCTrulicity$157$18,33111 claims
Johnson & JohnsonXarelto$35$12,05014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →